As an increasing number of Americans are faced with the difficult decision of whether to pursue hip or knee replacements, an increasing number of cases involving complications. This has given rise to hundreds of thousands of lawsuits, millions in medical expenses, and ongoing health issues for patients. Now Bristol-Meyers Squibb has announced that the U.S. Food and Drug Administration has approved a new supplemental drug for deep vain thrombosis, which could result in pulmonary embolism in patients who have undergone hip or knee replacement surgery.
The new drug, known as Eliquis is intended to prevent deep pain thrombosis in patients who have undergone hip or knee replacement. Advocates for the drug claim that the approval is a significant milestone for the medication and for the patients who suffer from additional health risks associated with knee and hip implants. Our Boston products liability attorneys are dedicated to helping victims or defective or dangerous products recover just compensation for their injuries. In addition to pursuing financial claims, we are committed to raising awareness surrounding the complications associated with medical device injury.
Continue reading